The development of multidrug resistance (MDR) is a major obstacle in cancer treatment by chemotherapy. Typical MDR displayed by tumor cells in vivo and cultured cells in vitro is characterized by their cross-resistance to a broad spectrum of structurally and functionally unrelated natural product cytotoxic agents, including vinca alkaloids, anthracyclines, and actinomycin D (13) . In cultured cells, the emergence of MDR is caused by the overexpression of a small group of highly conserved membrane phosphoglycoproteins named P-glycoproteins (P-gps) (13) . P-gps are encoded by a small family of genes, designated mdr orpgp, for which full-length cDNA clones have been isolated (8, 10, 14, 18, 20, 53) . Analysis of the predicted amino acid sequence indicates that P-gps are integral membrane proteins containing 12 predicted transmembrane (TM) domains and two intracellular loops with consensus ATP-binding motifs (8, 18) . P-gps have been shown to bind ATP and drug analogs (3) and to have ATPase activity (21) , suggesting that they function in resistant cells as energy-dependent efflux pumps of cytotoxic drugs.
A number of lipophilic compounds have been identified as capable of reversing the MDR phenotype in drug-resistant cells. These P-gp modulators, which include calcium channel blockers such as verapamil and azidopine, calmodulin inhibitors, indole alkaloids, progesterone, and cyclosporins, are 278 RAYMOND ET AL. revealed a previously unidentified potential clinical application for these compounds.
P-gps are members of a superfamily of evolutionarily conserved transport proteins termed the ABC (ATP-binding cassette) superfamily of proteins, involved in the transmembrane transport of structurally heterogeneous substrates (26) . The best-studied eukaryotic members of the ABC superfamily include thepftndrl gene product of Plasmodium falciparum, associated with chloroquine resistance (15) , the cystic fibrosis transmembrane conductance regulator protein, mutations in which lead to cystic fibrosis in humans (39) , and the yeast Saccharomyces cerevisiae STE6 gene product (30, 34) , which mediates the export of a-factor pheromone, a farnesylated dodecapeptide required for mating (35) . Yeast Ste6 and mammalian P-gps are over 50% homologous and have very similar predicted secondary structures and proposed membrane topologies (30, 34) . Recently, we have shown that the structural homology between the yeast and mammalian transporters translates into functional homology, since a cDNA for the mouse mdr3 gene can complement a null allele in a ste6 deletion strain, by restoring the ability of the cells to export a-factor and to mate (38) .
We 
MATERIALS AND METHODS
Yeast strains and culture media. S. cerevisiae JPY201, used throughout this study, was a gift from A. Varshavsky (California Institute of Technology, Pasadena) and has been previously described (34) . Its relevant genotype is AMTa ste6A ura3. Mating tester strain DC17 (MATa hisl) was a gift from M. Whiteway (Biotechnology Research Institute, Montreal, Quebec, Canada). Standard rich medium (YPD), synthetic medium lacking uracil (SD-Ura), and minimal medium were prepared as described elsewhere (45) .
Construction of mdr3 yeast expression plasmids. Plasmid pVT101-U (pVT) is a high-copy-number plasmid used for expression in yeast cells of the mouse mdr3 gene from the alcohol dehydrogenase promoter (54) . Plasmids pVT-MDR3S and pVT-MDR3F, which contain the mouse wildtype mdr3 gene and a mutant mdr3 derivative with a Ser-939-to-Phe substitution, respectively, have been described elsewhere (38) . To This modified mdr3 sequence was excised from plasmid pGEM-7Zf as a 4.1-kb fragment by digestion with SphI and ClaI, blunt ended with T4 DNA polymerase, and cloned into the PvuII site of pVTANruIAMCS to create pVT-MDR3S(3.4). Replacement of Ser-939 by Ala, Cys, Thr, Tyr, Trp, or Asp was carried out by standard site-directed mutagenesis using single-stranded M13 DNA templates as described elsewhere (12) . Reconstruction of these mutations into pVT-MDR3S(3.4) was performed by exchanging a wild-type NruI-PstI 785-bp fragment that overlaps amino acid position 939 by the corresponding mutagenized fragment, creating plasmids pVT-MDR3A, pVT-MDR3C, pVT-MDR3T, pVT-MDR3Y, pVT-MDR3W, and pVT-MDR3D, respectively. Presence of the desired mutation in the pVT-MDR3 plasmids was verified by DNA sequencing (42) , and integrity of restriction enzyme sites used for cloning was verified by fragmentation with the corresponding endonucleases. JPY201 cells were transformed with the various pVT derivatives by the lithium acetate method (27) (32) . Membranes were mixed with Laemmli sample buffer, incubated at room temperature for 20 min, and loaded on an SDS-7.5% polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane, and P-gps were identified by using the mouse monoclonal anti-P-gp antibody C219 (Centocor Corp., Philadelphia, Pa.) diluted at 1 ,ug/ml. Immune (48) . Overnight cultures of JPY201 transformants in SD-Ura medium were diluted (A6w = 0.7) and allowed to grow for 3 h at 30°C, after which time aliquots were taken for viable cell counts. Aliquots of the cultures were then mixed with 0.5 volume of a saturated overnight culture of tester strain DC17, and filtered on a nitrocellulose filter (0.45 ,m); the filters were incubated onto YPD agar plates for 4 h at 30°C to allow mating. Cells were then eluted from the filters with sterile water, and aliquots were plated onto minimal synthetic dextrose plates for the selection of diploids. Mating efficiency was calculated as the ratio of the number of diploids formed on selective medium to the number of haploid JPY201 cells introduced in the assay.
Antifungal antibiotics. FK520 (L-683,590) was kindly provided by Merck Sharp & Dohme Research Laboratories (Rahway, N.J.). FK520 is an FK506 analog containing an ethyl substituent replacing the allyl moiety at position C-21 of the macrolide ring (5). Stock solutions of the antibiotics were prepared at 10 mg/ml in methanol for liquid assays (5) or ethanol-10% Tween 20 as described previously (25) for plate assays.
Growth inhibition assays. FK520 resistance was tested by spotting portions (3 ,ul) of serially (10-fold) diluted overnight yeast cultures (grown in SD-Ura) onto YPD plates containing 100 ,ug of FK520 per ml. Control plates lacking FK520 contained ethanol and Tween 20 at the same concentrations as YPD plates containing FK520. Growth inhibition assays were routinely performed in YPD medium but could also be performed in selective medium (SD-Ura) without affecting the results. FK520 resistance was quantified by conventional microtitration techniques essentially as described previously (5) . Assays were performed in flat-bottom 96-well microtiter Laemmli sample buffer, and electrophoresed on an SDS-7.5% polyacrylamide gel. Fluorography of the gel was performed by using a commercially available amplifier (En3Hance; Du Pont) as recommended by the manufacturer.
The gel was dried and exposed for 24 h at -80°C. RESULTS Expression of mouse Mdr3 in yeast cells. Plasmids for expression of wild-type and mutant mouse mdr3 genes in the yeast S. cerevisiae have been described previously (38) . Briefly, a full-length cDNA for the mouse wild-type mdr3 gene was cloned into the yeast expression vector pVT, to produce plasmid pVT-MDR3S. pVT contains the 2p.m origin of replication for high copy number, the URA3 gene as a selectable marker, and the strong yeast alcohol dehydrogenase promoter (54) . A mutant mdr3 cDNA, encoding a Ser-to-Phe substitution at amino acid position 939, was also cloned into pVT, yielding plasmid pVT-MDR3F. The Ser-939-to-Phe substitution within predicted TM domain 11 of Mdr3 has been shown previously to decrease the activity and to modify the substrate specificity of this transporter for drugs of the MDR spectrum when overexpressed in cultured CHO cells (19, 28) . Plasmids pVT-MDR3S, pVT-MDR3F, and pVT were introduced into S. cerevisiae JPY201 (AM Ta ste6A::HIS3) (34) . Total membranes were prepared from the different transformants and analyzed by immunoblotting for the presence of immunoreactive wild-type and mutant Mdr3 proteins, using the mouse anti-P-gp monoclonal antibody C219 (Fig. 1A) . This antibody recognized P-gps with an apparent molecular mass of 125 kDa in membranes from VOL. 14, 1994 on presence of 100-, 1,000-, and 10,000-fold molar excesses of TPP (lanes 2 to 4, respectively) or 10-, 100-, and 1,000-fold molar excesses of VBL (lanes 5 to 7, respectively Fig. 2A, +ATP) or conditions of ATP depletion ( Fig. 2A, -ATP) , and drug accumulation was monitored over 60 min. Under normal metabolic conditions, Mdr3S spheroplasts accumulated little if any [3H]VBL, while Mdr3F spheroplasts accumulated the drug at levels undistinguishable from those observed in control spheroplasts ( Fig. 2A, +ATP) . The determine whether it could also confer drug resistance in yeast cells at the cellular level, as measured in cytotoxicity assays. Unfortunately, these efforts were unsuccessful since S. cerevisiae cells proved to be intrinsically resistant to common MDR drugs, including colchicine, VBL, adriamycin, and actinomycin D (data not shown). Recent reports have shown that the immunosuppressive agent FK506 is capable of functioning as an MDR reversal agent and substrate for P-gp (1, 36, 41) . The observation that FK506 and structural analogs also possess antifungal activity (5, 25) prompted us to investigate the interesting possibility that P-gp could confer cellular resistance in yeast cells to growth inhibition by this class of compounds.
For this purpose, a growth inhibition assay in liquid cultures was used to determine the level of sensitivity of JPY201 transformants to FK520, an FK506 analog with similar immunosuppressive and antifungal properties (5) . Figure 3A demonstrates that FK520 inhibits growth of pVT and Mdr3F transformants in a dose-dependent manner, exhibiting a 50% inhibitory concentration of approximately 40 ,ug/ml. In contrast, Mdr3S transformants were totally resistant to concentrations of FK520 as high as 100 ,ug/ml. It was not possible to determine the 50% inhibitory concentration for Mdr3S transformants in this type of assay, since 100 ,ug/ml represents the limit of solubility for FK520 in YPD culture medium. The effect of FK520 (at 100 ,ug/ml) on the growth rate of yeast transformants was also monitored over a period of 11 h in liquid cultures. Figure 3B shows Effects of Ser-939 mutations on FK520 resistance. To better understand the role of Ser-939 in the interaction of FK520 with P-gp and to identify the structural requirements involved in this interaction, we constructed Mdr3 expression vectors with this serine residue replaced by alanine, cysteine, threonine, tyrosine, tryptophan, and aspartic acid. We then tested the effects of these mutations on the ability of Mdr3 to confer FK520 resistance to yeast cells. Briefly, mutations were introduced by site-directed mutagenesis in mdr3 subfragments, and full-length mutant mdr3 clones were reconstructed by exchanging a wild-type mdr3 fragment from pVT-MDR3S with the corresponding mutagenized fragment, creating plasmids pVT-MDR3A, pVT-MDR3C, pVT-MDR3T, pVT-MDR3Y, pVT-MDR3W, and pVT-MDR3D. These plasmids, along with plasmids pVT-MDR3S, pVT-MDR3F, and pVT, were then transformed into strain JPY201, and mass populations of the resulting transformants were examined for their levels of resistance to FK520 by a spot test growth inhibition plate assay (Fig. 5) . Substitutions of Ser-939 were found to differentially modulate the ability of Mdr3 to confer cellular resistance to FK520, as yeast cells transformed with the different plasmids displayed either high levels of resistance (pVT-MDR3S, pVT-MDR3A, and pVT-MDR3C), a low level of resistance (pVT-MDR3T), or almost complete sensitivity (pVT-MDR3Y, pVT-MDR3W, pVT-MDR3F, and pVT-MDR3D) similar to that of pVT control cells.
We further quantitated the effects of the different mutations on the ability of Mdr3 to confer resistance to growth inhibition by FK520, using a liquid culture assay (Fig. 6) (12) . Taken together, these results indicate that the modulatory effect of independent Ser-939 mutations on Mdr3-mediated FK520 resistance in yeast cells is similar to the effect of these mutations on Mdr3-mediated drug resistance in mammalian cells. To verify that the biologically inactive Mdr3 mutants were properly expressed, yeast transformants were metabolically labelled, and labelled proteins were immunoprecipitated with an isoform-specific anti-Mdr3 polyclonal antibody (2037) described previously (6) . Figure 7 shows that the different transformants express similar amounts of wild-type or mutant Mdr3 proteins (lanes 2 to 9), absent from control pVT transformants (lane 1). Taken together, these results confirm that FK520 resistance detected in pVT-MDR3S cells (Fig. 3) is caused by functional P-gp expression and show that Ser-939 plays an important role in the interaction of FK520 with P-gp.
Effects of Ser-939 mutations on mating activity. We have shown that expression of mouse Mdr3 in a yeast ste6 deletion strain could functionally substitute for the yeast Ste6 transporter, by restoring the ability of the cells to export a-factor and to mate (38) . The introduction of the Ser-939-to-Phe substitution completely abolished the capacity of Mdr3 to complement the biological activity of Ste6, thereby indicating that Ser-939 is also an important determinant for a-factor transport. To determine whether the variations in levels of FK520 resistance observed between the different Mdr3 Ser-939 mutants were reflected by parallel modulation of a-factor transport activity, the mating efficiency of the transformants expressing the mutant Mdr3 proteins was measured by a quantitative mating assay (Fig.  5) . First, replacement of Ser-939 by Ala (pVT-MDR3A) had only a moderate effect on mating, resulting in a twofold decrease in mating efficiency compared with transformants 0.9. has been replaced by Ala, Cys, Thr, Tyr, Trp, Phe, or Asp to give plasmid pVT-MDR3A, pVT-MDR3C, pVT-MDR3T, pVT-MDR3Y, pVT-MDR3W, pVT-MDR3F, or pVT-MDR3D, respectively. The capacity of JPY201 transformants to mate with haploid AM Ta cells was determined and is expressed as the percentage relative to the value for pVT-MDR3S transformants, which was set at 100%. Values are means of three experiments (relative errors on each value were less than 50%). Yeast transformants were tested for resistance to FK520 by a spot test growth inhibition assay.
Equal numbers and serial 10-fold dilutions of each transformants were spotted on YPD plates containing FK520 at either 0 pLg/ml or 100 pLg/ml.
Plates were photographed after incubation at 30°C for 48 h.
expressing wild-type Mdr3 (pVT-MDR3S). Second, introduction of Cys (pVT-MDR3C) had a more pronounced effect on mating, generating mating efficiencies only 8% of that of the wild type. Third, substitution of Ser-939 by Thr (pVT-MDR3T) significantly reduced the mating activity of the transformants, which showed a mating efficiency approximately 2 orders of magnitude lower than that of Mdr3S-expressing cells. Finally, nonconservative substitutions at position 939 dramatically decreased (pVT-MDR3Y) or completely abolished (pVT-MDR3W, pVT-MDR3F, and pVT-MDR3D) the ability of Mdr3 to restore a-factor transport in yeast cells, resulting in 200-fold (Tyr) or at least 500-fold reductions in mating frequency of the corresponding transformants with respect to wild-type Mdr3S-expressing cells. Thus, the functional consequences of Ser-939 substitutions on a-factor transport and mating are strikingly similar to those observed for FK520 resistance. The analysis of independent mdr3 mutants suggests that Mdr3 expressed in yeast cells can transport both a-factor and FK520 and that the transport of these two substrates is by way of similar mechanisms.
DISCUSSION
Genetic analysis in prokaryotic (E. coli) or lower eukaryotic (yeast) cells provides a powerful approach to identify structure-function relationships in complex mammalian proteins. This technique is particularly useful for multispanning integral membrane proteins for which three-dimensional structure information is not available. While eukaryotic membrane proteins are often quite toxic to E. coli, resulting in no or only low levels of expression, this class of hydrophobic proteins appears to be particularly suited for expression in the yeast S. cerevisiae and Schizosaccharomyces pombe (see reference 55 and references therein). In an attempt to establish a simple system useful for the genetic and biochemical analysis of a mammalian P-gp, we have expressed a mouse mdr3 cDNA in S. cerevisiae. In a previous report, we showed that when expressed in a yeast ste6 deletion strain, P-gp encoded by mdr3 could functionally substitute for the yeast a-factor transporter Ste6, by restoring the ability of the cells to export a-factor and to mate (38) . In the present report, we demonstrate that in this (Fig. 4) . From these results, we conclude that P-gp expressed in S. cerevisiae is fully functional and acts as both a peptide and a drug transporter. The human MDRJ gene has also been successfully expressed in yeast cells, but the consequences of this expression on drug resistance and/or drug transport in these cells remain unclear, causing either increased (31) or decreased (40) cellular drug resistance.
The mechanism by which P-gp can recognize a large number of structurally and functionally unrelated substrates remains unsolved. Several biochemical and genetic lines of evidence suggest that the membrane-associated domains of P-gp are involved in that process (7, 11, 16, 33, 37) . We have recently documented that a single Ser-to-Phe substitution within TM domain 11 strongly modulates the activity of P-gps (19) . Biochemical analyses have shown that this mutation affects the capacity of P-gps to reduce cellular drug accumulation, to mediate efflux of drugs, and to bind photoactivable drug analogs (28) . In the present study, we demonstrate that when expressed in yeast cells, P-gp carrying the Ser-to-Phe mutation also displays a reduced capacity to bind [125I]IAAP and fails to transport VBL and to confer FK520 resistance. Thus, the effects of the Ser-to-Phe mutation in TM domain 11 of P-gp expressed in yeast cells, namely, impaired drug binding, transport, and resistance, are comparable to those observed when the same proteins are expressed in mammalian cells (19, 28) .
Replacement of Ser-939 by a series of amino acids (Ala, Cys, Thr, Tyr, Trp, and Asp) strongly modulates the capacity of P-gp encoded by mdr3 to confer resistance to a number of cytotoxic drugs and to transport adriamycin in mammalian cells, the size of the lateral chain rather than the charge appearing to be the primary structural determinant at that site (12) . Since our analysis of the Ser-to-Phe mutation in yeast cells indicated that Ser-939 is also important for the interaction of P-gp with a-factor and FK520, we have expressed these mdr3 mutants in yeast cells and tested the effects of these mutations on FK520 resistance and on mating. We show that substitution of Ser-939 in Mdr3 by different amino acids similarly modulates the level of FK520 resistance and the level of mating, in a manner that parallels the activity of these mutants for cytotoxic drugs in mammalian cells (12) . These results demonstrate that Ser-939 plays a key role in the interaction of P-gp not only with cytotoxic drugs such as colchicine, adriamycin, and actinomycin D but also with peptides such as a-factor and with immunosuppressive and fungicidal agents such as FK520. These results also clearly demonstrate that transport of both a-factor and FK520 in yeast cells is mechanistically similar to drug transport in mammalian cells. This further establishes the yeast system as a valid model for the structure-function analysis of P-gp.
The heterologous expression of mammalian P-gp in yeast cells provides two distinct phenotypes for mutational analysis of this transporter, namely, mating and FK520 resistance. These two phenotypes can be independently assayed for the functional screening of mutant P-gp molecules impaired in a-factor or FK520 transport and, most importantly, for the positive selection of second-site intragenic revertants of P-gp mutants inactive in each, or both, of these two processes.
The rapid isolation and analysis of second-site intragenic revertants of nonfunctional P-gp mutants should provide important information about interactions between specific structural and functional domains in P-gp. The yeast system may allow us to genetically dissect the mechanism of action of P-gp with respect to peptide and drug transport, an experimental strategy difficult in mammalian cells.
Understanding the mechanism of P-gp mediated transport requires knowledge of the structure of the protein. As yet, structural models for P-gp has relied principally on predictions from computer-based algorithms (8, 18) . However, recent studies have suggested a membrane organization for P-gp distinct from the generally accepted one predicted by hydropathy plot (46, 58) . The functional expression of P-gp as a drug-binding protein and transporter in yeast cells, described in this report, indicates that P-gp is properly targeted and inserted in the plasma membrane of yeast cells. Therefore, in the absence of three-dimensional structure for P-gp, the yeast system provides a valid tool with which to examine the topological arrangement of this membrane transporter, using a target-reporter gene fusion system. By fusing a truncated version of the HIS4 protein containing the histidinol dehydrogenase domain to specific TM domains of P-gp, it will be possible to evaluate the topology of specific positions within the protein in vivo (44) . A knowledge of the topology of the membrane-associated regions in P-gp should be important for future functional studies.
CsA, FK506, and rapamycin are natural products which possess potent immunosuppressive and antifungal properties (5, 24, 25) . While CsA is a cyclic undecapeptide, FK506 and rapamycin both belong to the macrolide antibiotic family (24, 43). The major cellular targets for these drugs, collectively designated immunophilins, are cyclophilin for CsA and FKBP for FK506 and rapamycin (24, 43) . Immunophilins are ubiquitous cytosolic proteins which possess peptidyl-propyl cis-trans isomerase activities and which are highly conserved phylogenetically (24, 43) . Fungal homologs of human cyclophilin and FKBP have been identified and shown to mediate CsA, rapamycin, and FK506 cytotoxicity in yeast cells (23, 29, 50 suggests that molecular recognition of FK506 in yeast and T cells may be related (5), although additional specific cellular targets in yeast cells appear to be required to mediate the antifungal activity of FK506 (23) . Such an FK506-sensitive target has recently been identified from S. cerevisiae and shown to be involved in amino acid import (22) .
In addition to their application as potent immunosuppressants, CsA, FK506, and rapamycin have been shown to function as effective P-gp modulators (1, 36) . The recent demonstration that CsA and FK506 are substrates for P-gp (41) coupled with the observation that they also possess antifungal activity (5, 23) prompted us to investigate whether P-gp could confer resistance in yeast cells to growth inhibition by this class of compounds. Using plate and liquid culture assays, we were able to demonstrate that yeast cells expressing P-gp encoded by mdr3 could grow in the presence of FK520, an FK506 analog with similar immunosuppressive and antifungal properties (5) . Results similar to those presented here for FK520 were obtained when the original compound FK506 was tested, indicating that substitution of the allyl moiety by an ethyl substituent at position C-21 on the macrolide ring does not affect the interaction of these compounds with P-gp (data not shown).
The identification of FK520 as a substrate for P-gp in yeast cells together with the amenability of the FK506 structure to chemical modifications (43) should prove extremely useful for structure-activity studies. As previously demonstrated for CsA (51) , the potent immunosuppressive properties of FK506 could be disadvantageous for its potential administration to cancer patients as a reversal agent. Consequently, the investigation of a series of chemically derived FK506 analogs in our yeast P-gp expression system should allow the identification of analogs with less immunosuppressive and better reversal activities for the treatment of MDR in vivo. The availability of a simple and fast microtiter assay will make it possible to investigate the activity of several chemical derivatives in combination with a large number of mutant P-gps. Such structure-activity relationship studies with a series of FK506 analogs should also prove useful for a better understanding of the structural requirement for efficient P-gp-FK506 interactions, allowing in turn the rational design of improved drugs and MDR modulators.
